Structural Heart Disease

Catch up on major trial results, groundbreaking guideline updates, and more.

Sorajja describes his team’s operation to implant the ring via a novel trans-septal system, effectively avoiding the need to stop the heart in MR treatment.

Catch up with major FDA decisions, critical conference news, and more.

Although the initial MACE composite outcome was not statistically significant, investigators saw follow-up MI risk reduced by >50%.

Research presented at the American Heart Association Scientific Sessions 2025 has emphasized the progress which still needs to be made in treating CHD.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.

Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.

Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.

Researchers indicated an association between the index and 365-day mortality.

Anita Radhakrishnan, MD, leads a community screening effort to detect early heart disease in underserved populations in Pittsburgh.

Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.

Marc Bonaca, MD, MPH, examines the benefit of semaglutide on functional outcomes in PAD from the STRIDE trial at ACC.25.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

Dapagliflozin lowered the incidence of all-cause death or worsening of heart failure versus standard care in the DapaTAVI trial at ACC.25.

The IND submission for VERVE-102 was supported by interim data from the dose-escalation portion of the ongoing Heart-2 Phase 1b clinical trial.

Bhatt previews 3 late-breaking clinical trials being presented at this year's American College of Cardiology Annual Scientific Sessions.

The regulatory agency accepted the BLA's filing and assigned a target action date of August 31, 2025.

Our top 5 headlines include 5 key FDA decisions, including the first approval for stroke in 3 decades, an expanded indication for pediatric anaphylaxis, and more!

The agency approved the first generic of the anticoagulant rivaroxaban to lower the risk of cardiovascular and thromboembolic events in adults with CAD and PAD.

Mehrdad Ghoreishi, MD explores the latest advances in aortic disease treatment and the role of minimally invasive techniques.

The American Heart Association’s 2025 statistical update confirms cardiovascular diseases claim more US lives than all forms of cancer and accidental deaths.